Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00733980 · ClinicalTrials.gov registry record · Phase 2
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00733980 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 150 participants.
The verdict
NCT00733980, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
Interventions
- OTHER Placebo
- DRUG GSK561679
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2008-10-02 |
| Est. Completion | 2010-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00733980
The ClinicalTrials.gov registry entry for NCT00733980 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00733980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00733980 about?
NCT00733980 is a clinical study titled "A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder". This six-week study will evaluate the efficacy, safety and tolerability of GSK561679 compared to placebo in female subjects with major depressive disorder
What is the current status of trial NCT00733980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2008-10-02. Estimated completion is 2010-06-18.
What interventions are being tested in trial NCT00733980?
The interventions under investigation include: Placebo (OTHER), GSK561679 (DRUG).
Who is sponsoring clinical trial NCT00733980?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.